Clinical trials: Female Breast Neoplasms
Breast Cancer
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
The purpose of this real-world study is to understand the use of palbociclib as first treatment for Hormone receptor positive (HR+) and Human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in Canada…
- Trial name
- NCT06003114
- Testing
- Palbociclib
- Where
- Canada
- Volunteers
- 472 people
- Sponsor
- Pfizer
Breast Cancer Female
Breast Cancer Screening in Ghana
This study is designed to test the feasibility of two intervention on promoting early screening for breast cancer in rural Ghana.
- Trial name
- NCT06362993
- Testing
- Bundling, MEGH
- Where
- Ghana
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Penn State University
Neoplasms, Breast Neoplasms
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone.
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Trial name
- MINT (NCT01151215)
- Testing
- AZD8931, anastrozole
- Where
- 60 sites in United States, Brazil and 16 more
- Volunteers
- 482 people
- Sponsor
- AstraZeneca
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer Female
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
The goal of this clinical trial is to develop an effective internet-delivered program to help breast cancer survivors manage cancer-related sexual concerns.
- Trial name
- SHINE (NCT06216574)
- Testing
- Internet-based Intervention
- Where
- 236 sites in United States
- Volunteers
- 340 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Major Depressive Episode
Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression
To provide evidence on the antidepressant efficacy of two therapeutic treatments: pharmacological treatment (citalopram) and psychotherapy treatment, in women diagnosed with breast cancer and major depression.
- Trial name
- CAMAD (NCT05063604)
- Testing
- Citalopram, Psychotherapy
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Universitari de Bellvitge
Breast Cancer
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer
This randomized phase II trial is studying how well genistein works in preventing breast cancer in women at high risk for breast cancer.
- Trial name
- NCT00290758
- Testing
- genistein, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- National Cancer Institute (NCI)
Cardiotoxicity, Breast Cancer
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate…
- Conditions
- Cardiotoxicity, Breast Cancer, Chemotherapy Induced Systolic Dysfunction
- Trial name
- EARLY-CATCH (NCT04046315)
- Testing
- CMR
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Radboud University Medical Center
Breast Cancer Female
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
- Trial name
- NeoATP (NCT04126525)
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 53 people
- Sponsor
- RenJi Hospital
Arrhythmias, Cardiac, Breast Cancer
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.
- Conditions
- Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer
- Trial name
- LEARN (NCT05184790)
- Where
- 4 sites in Australia
- Volunteers
- 300 people
- Sponsor
- University of Sydney
Breast Cancer Female, Sexual Dysfunction
Sexual Health and Breast Cancer: Developing Appropriate Education for Women Going Through Treatment
The purpose of this study is to assess the acceptability, appropriateness, and feasibility of a educational video series for patients going through breast cancer treatment.
- Trial name
- NCT06121258
- Testing
- Educational video series
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070278
- Testing
- cyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Cancer
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving anastrozole may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00283608
- Testing
- Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Mayo Clinic
Breast Neoplasms, Pain,Postoperative
Chlorhydrate of Ropivacaine and Breast Cancer Surgery
The aim of the study is to evaluate the effect of local anesthetic (chlorhydrate of ropivacaine) to prevent chronic pain after breast surgery for cancer.
- Trial name
- NCT00370240
- Testing
- Chlorhydrate de Ropivacaine
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Institut Curie
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Anemia, Breast Neoplasms
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
The purpose of this study is to evaluate the impact on survival and quality of life of maintaining hemoglobin in the range of 12 to 14 g/dL using epoetin alfa or placebo in patients starting chemotherapy for metastatic breast…
- Conditions
- Anemia, Breast Neoplasms, Quality of Life
- Trial name
- NCT00211133
- Testing
- epoetin alfa
- Volunteers
- 939 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cancer
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who…
- Trial name
- NCT00949052
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Carcinoma, Male Breast Carcinoma
Access to Genetic Testing in Underserved Patients With Cancer
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider.
- Conditions
- Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma
- Trial name
- NCT06422455
- Testing
- Best Practice, Educational Intervention, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Southern California